Carer utilities in Alzheimer’s Disease

Off

NICE appraisals

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

DSU Report

Pennington B, Mon-Yee M. Carers’ health-related quality of life in Alzheimer’s Disease. A NICE DSU Report. May 2026.

Background 

This project aims to understand what evidence on caregiver utilities in Alzheimer’s was presented to the committees, whether EQ-5D is adequate in this population, and whether there are additional sources of caregiver utility values that may be useful in populating the economic models.